X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (527) 527
fibric acids (348) 348
male (281) 281
hypolipidemic agents - therapeutic use (278) 278
female (222) 222
fibric acids - therapeutic use (220) 220
middle aged (176) 176
pharmacology & pharmacy (173) 173
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (166) 166
fenofibrate (165) 165
animals (128) 128
aged (126) 126
fenofibrate - therapeutic use (125) 125
risk factors (125) 125
statins (112) 112
coronary-heart-disease (110) 110
cholesterol (109) 109
dyslipidemias - drug therapy (105) 105
gemfibrozil (103) 103
adult (102) 102
treatment outcome (100) 100
clofibric acid - analogs & derivatives (97) 97
clofibric acid - therapeutic use (96) 96
triglycerides - blood (96) 96
cardiac & cardiovascular systems (91) 91
triglycerides (87) 87
atherosclerosis (84) 84
cardiovascular diseases - prevention & control (84) 84
drug therapy, combination (81) 81
fibrates (81) 81
medicine & public health (81) 81
cholesterol, hdl - blood (80) 80
lipids (78) 78
diabetes (77) 77
hyperlipidemias - drug therapy (77) 77
research (71) 71
cholesterol, ldl - blood (65) 65
hypolipidemic agents - adverse effects (65) 65
hypolipidemic agents - pharmacology (63) 63
lipids - blood (63) 63
dyslipidemia (62) 62
endocrinology & metabolism (61) 61
pharmacology/toxicology (61) 61
niacin - therapeutic use (60) 60
analysis (59) 59
cardiovascular disease (59) 59
risk (59) 59
peripheral vascular disease (58) 58
care and treatment (57) 57
cardiovascular-disease (56) 56
medicine, general & internal (56) 56
cardiovascular (55) 55
type 2 diabetes (53) 53
bezafibrate (50) 50
low density lipoproteins (50) 50
mice (50) 50
anticholesteremic agents - therapeutic use (49) 49
internal medicine (49) 49
therapy (49) 49
cardiovascular diseases (48) 48
type-2 diabetes-mellitus (48) 48
cardiovascular diseases - etiology (47) 47
metabolic syndrome (47) 47
diabetes mellitus, type 2 - drug therapy (46) 46
drug therapy (45) 45
hypertriglyceridemia - drug therapy (45) 45
hypolipidemic agents - administration & dosage (45) 45
myocardial-infarction (45) 45
secondary prevention (45) 45
diabetes mellitus, type 2 - complications (44) 44
fenofibrate - pharmacology (44) 44
health aspects (44) 44
prevention (44) 44
drug interactions (43) 43
dyslipidemias - blood (42) 42
randomized controlled trials as topic (42) 42
atorvastatin (41) 41
cardiology (41) 41
hyperlipidemia (41) 41
metabolism (41) 41
abridged index medicus (40) 40
rats (40) 40
simvastatin (40) 40
drugs (39) 39
ezetimibe (39) 39
physiological aspects (39) 39
cholesterol - blood (38) 38
dyslipidemias - complications (38) 38
hypercholesterolemia (38) 38
time factors (38) 38
toxicology (38) 38
gemfibrozil - therapeutic use (37) 37
ppar-alpha (37) 37
hyperlipidemias - blood (35) 35
diabetes mellitus, type 2 - blood (34) 34
fenofibrate - administration & dosage (34) 34
fibric acids - adverse effects (34) 34
ciprofibrate (33) 33
insulin resistance (33) 33
lipoproteins (33) 33
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (653) 653
French (9) 9
Spanish (9) 9
Japanese (7) 7
German (6) 6
Russian (6) 6
Hungarian (4) 4
Portuguese (3) 3
Czech (2) 2
Polish (2) 2
Danish (1) 1
Italian (1) 1
Romanian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2015, Volume 2018, Issue 4, p. CD009580
Background Fibrates are a class of drugs characterised by mainly lowering high triglyceride, raising high‐density lipoprotein (HDL) cholesterol, and lowering... 
Drugs | Cardiovascular Diseases | Costs | A. Cardiovascular Disease: Primary Prevention | Secondary Prevention | Insurance medicine | Cause of Death | Prevention | Coronary Disease | Cholesterol, HDL | Fibric Acids | Heart & circulation | A.1 Drugs | Anticholesteremic Agents | Stroke | Heart disease prevention | Clofibrate | A.1.2 Lipid Lowering | Randomized Controlled Trials as Topic | Fenofibrate | Myocardial Infarction | Bezafibrate | Hypertriglyceridemia | Gemfibrozil | Medicine General & Introductory Medical Sciences | EXTREMITY ARTERIAL-DISEASE | MEDICINE, GENERAL & INTERNAL | COMBINED HYPERLIPIDEMIA | MYOCARDIAL-INFARCTION | INTERVENTION TRIAL | COMBINATION THERAPY | DOUBLE-BLIND | CORONARY-HEART-DISEASE | TYPE-2 DIABETES-MELLITUS | FENOFIBRATE INTERVENTION | HIGH-DENSITY-LIPOPROTEIN | Hypertriglyceridemia - drug therapy | Fibric Acids - therapeutic use | Myocardial Infarction - mortality | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Gemfibrozil - therapeutic use | Male | Secondary Prevention - methods | Fenofibrate - therapeutic use | Coronary Disease - mortality | Fibric Acids - adverse effects | Clofibrate - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - mortality | Adult | Female | Stroke - mortality | Bezafibrate - therapeutic use | Stroke - prevention & control | Anticholesteremic Agents - therapeutic use | Aged | Myocardial Infarction - prevention & control
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 23, pp. 2171 - 2181
In a randomized trial of patients with primary biliary cholangitis, bezafibrate and ursodeoxycholic acid resulted in a higher rate of complete biochemical response than ursodeoxycholic acid alone... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | OBETICHOLIC ACID | URSODEOXYCHOLIC ACID | PROGNOSIS | COMBINATION THERAPY | CIRRHOSIS | RENAL-FUNCTION | BIOCHEMICAL RESPONSE | OUTCOMES | FENOFIBRATE THERAPY | Bezafibrate - therapeutic use | Hypolipidemic Agents - adverse effects | Bile Acids and Salts - blood | Double-Blind Method | Humans | Middle Aged | Liver Cirrhosis, Biliary - drug therapy | Male | Bezafibrate - adverse effects | Cholangitis - drug therapy | Ursodeoxycholic Acid - therapeutic use | Cholangitis - etiology | Placebos - therapeutic use | Treatment Failure | Adult | Female | Hypolipidemic Agents - therapeutic use | Liver Cirrhosis, Biliary - complications | Usage | Care and treatment | Dosage and administration | Biliary cirrhosis | Research | Health aspects | Fibric acids | Antilipemic agents | Alkaline phosphatase | Laboratories | Liver | Gallbladder diseases | Biochemistry | Pruritus | Bilirubin | Phosphatase | Ursodeoxycholic acid | Hepatitis | Hepatology | Gastroenterology | Tumor necrosis factor-TNF | Creatinine | Hypertension | Liver diseases | Cholangitis | Fatigue | Myalgia | Patients | Cholesterol | Quality of life | Hospitals | Acids | Bezafibrate | Fibrosis | Prothrombin | Peroxisome proliferator-activated receptors | Bile | Life Sciences | Human health and pathology
Journal Article
European heart journal, ISSN 1522-9645, 2011, Volume 32, Issue 11, pp. 1345 - 1361
Journal Article
Journal Article
Journal Article
European heart journal, ISSN 1522-9645, 2009, Volume 31, Issue 2, pp. 149 - 164
Journal Article
Journal Article